Ranbaxy, Teva To Appeal Injunction Against Accupril Generics

Law360, New York (March 30, 2005, 12:00 AM EST) -- Indian drug maker Ranbaxy Laboratories Ltd. and Israeli partner Teva Pharmaceuticals have vowed to file an immediate appeal of a New Jersey federal court’s preliminary injunction against sales of a generic version of Pfizer’s hypertension drug Accupril.

“While Teva and Ranbaxy will comply with the preliminary injunction, they also will immediately file with the U.S. Court of Appeals for the Federal Circuit an appeal to have the injunction lifted and a motion to expedite the appeal,” said Jay Deshmukh, Ranbaxy's Vice President for Intellectual Property....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.